Potential molecular therapeutic targets in cancer stem/progenitor cells: Are ATP-binding cassette membrane transporters appropriate targets to eliminate cancer-initiating cells?

Murielle Mimeault, Surinder Kumar Batra

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Citations (Scopus)

Abstract

Recent advances in the basic and clinical oncology have revealed that the malignant transformation of the tissue-resident adult stem/progenitor cells into leukemic or tumorigenic cancer stem/progenitor cells plays a central role in the etiopathogenesis and progression of the most human cancers. Cancer stem/progenitor cells endowed with a high self-renewal capacity and aberrant differentiation potential generally possess the high expression levels and activity of diverse ATP-binding cassette (ABC) transporters, DNA repair and detoxifying enzymes and anti-apoptotic factors. These phenotypic and functional features common to the most of cancer stem/progenitor cells have been associated with their intrinsic or acquired resistance phenotype to numerous chemotherapeutic drugs, disease recurrence and poor patient survival. Moreover, the sustained activation of distinct oncogenic signaling elements in these immature cancer-initiating cells during disease progression may also contribute to their acquisition of a more malignant behavior and development of metastatic disease state. Of particular interest, we describe the potential therapeutic targets to eradicate the cancer-initiating cells and their mature progenies in a variety of aggressive human cancers such as leukemias, melanoma and solid tumors including brain and epithelial cancers. The emphasis is on potential therapeutic molecular targets in cancer stem/progenitor cells and their progenies including ABC drug transporters, ceramide, telomerase, and diverse tumorigenic signaling elements.

Original languageEnglish (US)
Title of host publicationStem Cell Biology in Health and Disease
PublisherSpringer Netherlands
Pages385-421
Number of pages37
ISBN (Print)9789048130399
DOIs
StatePublished - Dec 1 2009

Fingerprint

ATP-Binding Cassette Transporters
Membrane Transport Proteins
Neoplastic Stem Cells
Stem cells
Stem Cells
Adenosine Triphosphate
Neoplasms
DNA Repair Enzymes
Therapeutics
Adult Stem Cells
Oncology
Medical Oncology
Ceramides
Telomerase
Brain Neoplasms
Pharmaceutical Preparations
Disease Progression
Tumors
Melanoma
Brain

Keywords

  • ATP-binding cassette transporters
  • Cancer stem/progenitor cells
  • Cancer therapies
  • Combination therapies
  • Drug targets
  • Leukemias
  • Molecular targeting
  • Multidrug resistance
  • Oncogenic signaling elements
  • Solid tumors

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Potential molecular therapeutic targets in cancer stem/progenitor cells : Are ATP-binding cassette membrane transporters appropriate targets to eliminate cancer-initiating cells? / Mimeault, Murielle; Batra, Surinder Kumar.

Stem Cell Biology in Health and Disease. Springer Netherlands, 2009. p. 385-421.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{d003743bd7d249deb81fdc7560220068,
title = "Potential molecular therapeutic targets in cancer stem/progenitor cells: Are ATP-binding cassette membrane transporters appropriate targets to eliminate cancer-initiating cells?",
abstract = "Recent advances in the basic and clinical oncology have revealed that the malignant transformation of the tissue-resident adult stem/progenitor cells into leukemic or tumorigenic cancer stem/progenitor cells plays a central role in the etiopathogenesis and progression of the most human cancers. Cancer stem/progenitor cells endowed with a high self-renewal capacity and aberrant differentiation potential generally possess the high expression levels and activity of diverse ATP-binding cassette (ABC) transporters, DNA repair and detoxifying enzymes and anti-apoptotic factors. These phenotypic and functional features common to the most of cancer stem/progenitor cells have been associated with their intrinsic or acquired resistance phenotype to numerous chemotherapeutic drugs, disease recurrence and poor patient survival. Moreover, the sustained activation of distinct oncogenic signaling elements in these immature cancer-initiating cells during disease progression may also contribute to their acquisition of a more malignant behavior and development of metastatic disease state. Of particular interest, we describe the potential therapeutic targets to eradicate the cancer-initiating cells and their mature progenies in a variety of aggressive human cancers such as leukemias, melanoma and solid tumors including brain and epithelial cancers. The emphasis is on potential therapeutic molecular targets in cancer stem/progenitor cells and their progenies including ABC drug transporters, ceramide, telomerase, and diverse tumorigenic signaling elements.",
keywords = "ATP-binding cassette transporters, Cancer stem/progenitor cells, Cancer therapies, Combination therapies, Drug targets, Leukemias, Molecular targeting, Multidrug resistance, Oncogenic signaling elements, Solid tumors",
author = "Murielle Mimeault and Batra, {Surinder Kumar}",
year = "2009",
month = "12",
day = "1",
doi = "10.1007/978-90-481-3040-5_17",
language = "English (US)",
isbn = "9789048130399",
pages = "385--421",
booktitle = "Stem Cell Biology in Health and Disease",
publisher = "Springer Netherlands",

}

TY - CHAP

T1 - Potential molecular therapeutic targets in cancer stem/progenitor cells

T2 - Are ATP-binding cassette membrane transporters appropriate targets to eliminate cancer-initiating cells?

AU - Mimeault, Murielle

AU - Batra, Surinder Kumar

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Recent advances in the basic and clinical oncology have revealed that the malignant transformation of the tissue-resident adult stem/progenitor cells into leukemic or tumorigenic cancer stem/progenitor cells plays a central role in the etiopathogenesis and progression of the most human cancers. Cancer stem/progenitor cells endowed with a high self-renewal capacity and aberrant differentiation potential generally possess the high expression levels and activity of diverse ATP-binding cassette (ABC) transporters, DNA repair and detoxifying enzymes and anti-apoptotic factors. These phenotypic and functional features common to the most of cancer stem/progenitor cells have been associated with their intrinsic or acquired resistance phenotype to numerous chemotherapeutic drugs, disease recurrence and poor patient survival. Moreover, the sustained activation of distinct oncogenic signaling elements in these immature cancer-initiating cells during disease progression may also contribute to their acquisition of a more malignant behavior and development of metastatic disease state. Of particular interest, we describe the potential therapeutic targets to eradicate the cancer-initiating cells and their mature progenies in a variety of aggressive human cancers such as leukemias, melanoma and solid tumors including brain and epithelial cancers. The emphasis is on potential therapeutic molecular targets in cancer stem/progenitor cells and their progenies including ABC drug transporters, ceramide, telomerase, and diverse tumorigenic signaling elements.

AB - Recent advances in the basic and clinical oncology have revealed that the malignant transformation of the tissue-resident adult stem/progenitor cells into leukemic or tumorigenic cancer stem/progenitor cells plays a central role in the etiopathogenesis and progression of the most human cancers. Cancer stem/progenitor cells endowed with a high self-renewal capacity and aberrant differentiation potential generally possess the high expression levels and activity of diverse ATP-binding cassette (ABC) transporters, DNA repair and detoxifying enzymes and anti-apoptotic factors. These phenotypic and functional features common to the most of cancer stem/progenitor cells have been associated with their intrinsic or acquired resistance phenotype to numerous chemotherapeutic drugs, disease recurrence and poor patient survival. Moreover, the sustained activation of distinct oncogenic signaling elements in these immature cancer-initiating cells during disease progression may also contribute to their acquisition of a more malignant behavior and development of metastatic disease state. Of particular interest, we describe the potential therapeutic targets to eradicate the cancer-initiating cells and their mature progenies in a variety of aggressive human cancers such as leukemias, melanoma and solid tumors including brain and epithelial cancers. The emphasis is on potential therapeutic molecular targets in cancer stem/progenitor cells and their progenies including ABC drug transporters, ceramide, telomerase, and diverse tumorigenic signaling elements.

KW - ATP-binding cassette transporters

KW - Cancer stem/progenitor cells

KW - Cancer therapies

KW - Combination therapies

KW - Drug targets

KW - Leukemias

KW - Molecular targeting

KW - Multidrug resistance

KW - Oncogenic signaling elements

KW - Solid tumors

UR - http://www.scopus.com/inward/record.url?scp=84888200489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888200489&partnerID=8YFLogxK

U2 - 10.1007/978-90-481-3040-5_17

DO - 10.1007/978-90-481-3040-5_17

M3 - Chapter

AN - SCOPUS:84888200489

SN - 9789048130399

SP - 385

EP - 421

BT - Stem Cell Biology in Health and Disease

PB - Springer Netherlands

ER -